ASK REDCHAT ANYTHING ABOUT CANDEL THERAPEUTICS INC.
Candel Therapeutics Inc. (NASDAQ: CADL)
Listen to this Section
$8.53
-0.7450
(
-8.04% )
1.3M
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| CAN-2409DetailsCancer, Solid tumor/s, Intermediate/high-risk Prostate cancerBig Mover™Suspected Mover™Susp. Mover™ |
Phase 3 |
| CAN-2409DetailsCancer, Solid tumor/s, Low-to-intermediate-risk non-metastatic prostate cancer |
Phase 2b |
| CAN-2409 + Valacyclovir w/ SoCDetailsPancreatic cancer, Cancer |
Phase 2 |
| CAN-2409 + Valacyclovir w/ PD-(L)1 targeting agentsDetailsLung cancer, Cancer, Solid tumor/s, Non-small cell lung carcinoma |
Phase 2 |
| CAN-3110DetailsSolid tumor/s, Cancer, Glioma |
Phase 1b |
| CAN-2409 + OpdivoDetailsCancer, Glioma, Solid tumor/s |
Failed |
Market Data
|
| Open |
$8.53 |
| Previous Close |
$9.27 |
| Volume |
1.3M |
| Market Cap |
$644.78M |
| Day Range |
$8.53 - $9.44 |
| 52 Week Range |
$4.35 - $9.57 |
| Shares Outstanding |
73.27M |
| Change % |
-8.04% |
| Net Change |
▼ -0.7450 |
| Insider Ownership |
-0.02% |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations |
| IPO Year | 2021 |
| Country | United States |
| Underwriter | Jefferies, Credit Suisse, BMO Capital Markets, UBS Investment Bank, more |
Insider Ownership Transactions
Total Amount Purchased:
74,615.00
| Date |
Type |
Amount Purchased |
Purchaser |
| 2026-02-26 |
Buy |
550458.00 |
Manning Paul B |
| 2024-12-18 |
Buy |
500000.00 |
Manning Paul B |
| 2024-07-19 |
Sale |
-14851.00 |
Tyagarajan Seshu |
| 2024-07-19 |
Sale |
-22528.00 |
Tak Paul Peter |
| 2024-07-19 |
Sale |
-14051.00 |
Barone Francesca |
| 2024-07-19 |
Sale |
-9884.00 |
Schoch Charles |
| 2024-07-19 |
Sale |
-10875.00 |
Nichols William Garrett |
| 2024-07-15 |
Sale |
-9769.00 |
Nichols William Garrett |
| 2024-07-15 |
Sale |
-12645.00 |
Barone Francesca |
| 2024-07-15 |
Sale |
-20293.00 |
Tak Paul Peter |